Physician profile
Mark E Hostettler
NPI 1265431753
$8,971.48
in general payments reported to CMS, 2019-2025
59 companies · $773 in 2025
The $773 reported for 2025 was more than what 81% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,434 · 2020: $1,377 · 2021: $1,769 · 2022: $1,536 · 2023: $979 · 2024: $1,104 · 2025: $773.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,856.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,856.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $902.82 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $828.65 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Amarin Pharma, INC. | $742.42 | 2019-2022 | |
| Lilly USA, LLC | $694.44 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $524.49 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Janssen Pharmaceuticals, INC | $498.16 | 2019-2023 | Xarelto |
| Abbvie INC. | $478.95 | 2019-2024 | |
| Allergan, INC. | $472.71 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $445.64 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Takeda Pharmaceuticals U.S.A., INC. | $310.10 | 2019-2024 | Trintellix |
| Glaxosmithkline, LLC. | $271.98 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $241.80 | 2020-2025 | Jardiance, Tradjenta, Synjardy |
| Welch Allyn | $225.00 | 2021 | |
| Novartis Pharmaceuticals Corporation | $217.01 | 2021-2025 | |
| Antares Pharma, INC. | $198.82 | 2019-2025 | Xyosted |
Show all 59 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Hostettler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.